Thomas F. Isett
Director Ejecutivo en Transposagen Biopharmaceuticals, Inc. .
Fortuna: 1 428 $ al 31/05/2024
Perfil
Thomas F.
Isett is currently the Chief Executive Officer at Transposagen Biopharmaceuticals, Inc. and Chairman & Chief Executive Officer at iBio CDMO LLC.
Previously, he served as the Chief Executive Officer & Director at iBio, Inc. from 2019 to 2022.
He also held positions as the Chief Executive Officer at Commence Biologics, Inc., Managing Director at i.e.
Advising LLC, Vice President-Advanced Bioprocessing at Becton, Dickinson & Co., and General Manager-BioProcess at GE Aerospace.
From 2009 to 2012, he was the Head-Cell Processing Technologies at Lonza AG.
Mr. Isett completed his undergraduate degree at Drexel University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IBIO, INC.
0.01% | 25/10/2023 | 600 ( 0.01% ) | 1 428 $ | 31/05/2024 |
Cargos activos de Thomas F. Isett
| Empresas | Cargo | Inicio |
|---|---|---|
Transposagen Biopharmaceuticals, Inc.
 Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Director Ejecutivo | 01/08/2017 |
iBio CDMO LLC
 iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Director Ejecutivo | - |
Antiguos cargos conocidos de Thomas F. Isett.
| Empresas | Cargo | Fin |
|---|---|---|
| IBIO, INC. | Director Ejecutivo | 01/12/2022 |
Lonza AG
 Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Corporate Officer/Principal | 01/01/2012 |
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | 01/01/2009 |
| Commence Biologics, Inc. | Director Ejecutivo | - |
| i.e. Advising LLC | Director Ejecutivo | - |
Formación de Thomas F. Isett.
| Drexel University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| IBIO, INC. | Health Technology |
| GE AEROSPACE | Producer Manufacturing |
| BECTON, DICKINSON AND COMPANY | Health Technology |
| Empresas privadas | 5 |
|---|---|
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Health Technology |
Lonza AG
Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Health Technology |
| i.e. Advising LLC | |
| Commence Biologics, Inc. | |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas F. Isett
